Adjuvant Camrelizumab Plus Capecitabine in Intrahepatic Cholangiocarcinoma After Surgical Resection: Chinese Phase 2 Trial
Adjuvant camrelizumab combined with capecitabine demonstrated encouraging activity and acceptable tolerability in patients with R0‑resected intrahepatic cholangiocarcinoma.
The ACC trial evaluated whether combining camrelizumab with capecitabine could improve recurrence outcomes in patients with resected intra‑hepatic cholangiocarcinoma. 65 patients were enrolled and followed for a median of 33.7 months. Median recurrence‑free survival was 24.29 months (95% CI 13.54‑not reached). The combination demonstrated encouraging activity and acceptable tolerability.
Recurrence after resection of intra‑hepatic cholangiocarcinoma remains high; this study suggests that adjuvant PD‑1 blockade plus chemotherapy may improve recurrence‑free survival and could inform future randomized trials.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
- Scientists build cell line atlas of deadly cancers of the bile ducts and gallbladder
- Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures
- New EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma
- An open‑label study of pemigatinib in cholangiocarcinoma: final results from FIGHT‑202